Last updated on February 2018

French Registry of First-line Treatment of Acute Promyelocytic Leukemia


Brief description of study

The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.

Detailed Study Description

  • Collection of epidemiological data on non-high-risk APL patients aged 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status).
    • Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients.
    • Documentation of Minimal Residual Disease (MRD).
    • Correlation of clinical outcomes with the chosen therapy.
    • Validation of published prognostic factors and identification of new prognostic factors

Clinical Study Identifier: NCT02938858

Find a site near you

Start Over

CH Dr Schaffner

Lens, France
9.9miles
  Connect »